Xi'an-Janssen Pharmaceutical Ltd.

Pharmaceutical company, a joint venture of Johnson & Johnson in China.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

• New hope for Crohn's patients: study tests guselkumab after ustekinumab fails Results expected Sep 2027 (estimated)